Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

InMed Pharmaceuticals (INM) Depreciation & Amortization (IS) (2019 - 2026)

InMed Pharmaceuticals has reported Depreciation & Amortization (IS) over the past 5 years, most recently at $53201.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (IS) changed 0.0% year-over-year to $53201.0; the TTM value through Dec 2025 reached $211461.0, down 2.69%, while the annual FY2025 figure was $212839.0, 3.08% down from the prior year.
  • Depreciation & Amortization (IS) for Q4 2025 was $53201.0 at InMed Pharmaceuticals, roughly flat from $53202.0 in the prior quarter.
  • Over five years, Depreciation & Amortization (IS) peaked at $55234.0 in Q4 2023 and troughed at $28532.0 in Q3 2021.
  • A 5-year average of $51486.0 and a median of $53202.0 in 2024 define the central range for Depreciation & Amortization (IS).
  • Biggest five-year swings in Depreciation & Amortization (IS): skyrocketed 71.91% in 2022 and later fell 4.97% in 2023.
  • Year by year, Depreciation & Amortization (IS) stood at $49797.0 in 2021, then decreased by 1.5% to $49049.0 in 2022, then grew by 12.61% to $55234.0 in 2023, then decreased by 3.68% to $53202.0 in 2024, then fell by 0.0% to $53201.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (IS) for INM at $53201.0 in Q4 2025, $53202.0 in Q3 2025, and $52752.0 in Q2 2025.